Online inquiry

IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2778MR)

This product GTTS-WQ2778MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL1RL1 gene. The antibody can be applied in Allergic asthma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001282408.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 9173
UniProt ID Q01638
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2778MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14956MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SHR-1210
GTTS-WQ920MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-221
GTTS-WQ15671MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA VB6-845
GTTS-WQ12564MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NV-02
GTTS-WQ11291MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-522
GTTS-WQ15770MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ13266MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06252616
GTTS-WQ12533MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NPVPDR001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW